journal article·2025-10-01

Multi breast cells-on-a-chip: efficient screening biological platform for determination of selective breast cancer cell apoptosis

Bumjun Park, Eun-Ho Lee, Jigyeong Kim, Ju Yong Sung, Yun Suk Huh, Sung-Min Kang

Biofabrication· Volume 17· Issue 4
Publisher page

Abstract

Abstract In this study, a multi breast cell-on-a-chip system was developed to recapitulate human-like breast cancer microenvironments by simultaneously co-culturing normal (MCF-10 A) and breast cancer cell lines (MCF-7 and MDA-MB-231) and to confirm the potential of plasma-activated PBS (P-PBS) containing various reactive oxygen species (ROS), as selective breast cancer remedial agent. The developed chip not only provided a 3D microenvironment supporting cell survival and interactions due to the use of gelatin as an extracellular matrix but also facilitated homogeneous growth and interactions between the different breast cell lines. Moreover, selective breast cancer apoptosis was investigated by real-time image analysis after treating cells with P-PBS on the developed chip; IC50 values for MCF-7 and MDA-MB-231 were 390.50 and 600.75 μM, respectively. In addition, the breast cancer cell apoptosis pathway was found to be related to the ROS-activated intrinsic apoptosis pathway. The developed multi breast cells-on-a-chip platform could be used as a bio-platform that complements the limitations of existing in vitro models. The chip accurately reproduces cell-to-cell interactions by providing a tumor microenvironment based on the co-culture of heterogeneous cancer and normal cells and is expected to contribute meaningfully to breast cancer research and customized treatment development.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Neuroscience and Neural Engineering · Cancer Cells and Metastasis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (72)

Show source-provided references
1. Breast cancer treatment: a review10.1001/jama.2018.19323 ↗
2. PD-L1 status in breast cancer: current view and perspectives10.1016/j.semcancer.2019.12.003 ↗
3. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ–the LORD study10.1016/j.ejca.2015.05.008 ↗
4. MCF-7: a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors10.1016/0039-128X(75)90110-5 ↗
5. Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells10.1016/j.canlet.2011.04.009 ↗
6. Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT–tamoxifen hybrid therapy10.1038/s41523-019-0108-8 ↗
7. pH-activatable cell penetrating peptide dimers for potent delivery of anticancer drug to triple-negative breast cancer10.1016/j.jconrel.2020.10.063 ↗
8. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival10.1073/pnas.0909333107 ↗
9. Targeting the warburg effect that arises in tumor cells expressing membrane type-1 matrix metalloproteinase10.1074/jbc.M110.188714 ↗
10. Recent advances in the treatment of breast cancer10.3389/fonc.2018.00227 ↗
11. Current status and limitations of immunotherapy for breast cancer10.1016/j.surg.2019.09.018 ↗
12. Research needs in breast cancer10.1093/annonc/mdw571 ↗
13. Breast cancer stem cells: implications for therapy of breast cancer10.1186/bcr2111 ↗
14. Single-molecule experiments in vitro and in silico10.1126/science.1137591 ↗
15. Meta‐analysis of the relationship between dietary tannin level and methane formation in ruminants from in vivo and in vitro experiments10.1111/j.1439-0396.2011.01172.x ↗
16. From in vitro experiments to in vivo and clinical studies; pros and cons10.2174/1570163813666160114093140 ↗
17. From cells-on-a-chip to organs-on-a-chip: scaffolding materials for 3D cell culture in microfluidics10.1039/D0TB00718H ↗
18. Immune organs and immune cells on a chip: an overview of biomedical applications10.3390/mi11090849 ↗
19. One-step evaluation of doxorubicin toxicity through concentration gradient generator integrating breast cancer-on-a-chip10.1007/s13206-025-00192-4 ↗
20. From single- to multi-organ-on-a-chip system for studying metabolic diseases10.1007/s13206-023-00098-z ↗
21. Culture and analysis of kidney tubuloids and perfused tubuloid cells-on-a-chip10.1038/s41596-020-00479-w ↗
22. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer10.1007/s10549-022-06633-0 ↗
23. Glucocorticoids induce production of reactive oxygen species/reactive nitrogen species and DNA damage through an iNOS mediated pathway in breast cancer10.1186/s13058-017-0823-8 ↗
24. Tailoring supramolecular prodrug nanoassemblies for reactive nitrogen species-potentiated chemotherapy of liver cancer10.1021/acsnano.1c00698 ↗
25. Immunoregulatory and effector activities of nitric oxide and reactive nitrogen species in cancer10.2174/0929867323666160727105101 ↗
26. Enhanced cisplatin chemotherapy by iron oxide nanocarrier-mediated generation of highly toxic reactive oxygen species10.1021/acs.nanolett.6b04269 ↗
27. The role of cellular reactive oxygen species in cancer chemotherapy10.1186/s13046-018-0909-x ↗
28. Reactive oxygen species: beyond their reactive behavior10.1007/s11064-020-03208-7 ↗
29. Approaching reactive species in the frame of their clinical significance: a toxicological appraisal10.1016/j.fct.2020.111206 ↗
30. Oxygen, reactive oxygen species and tissue damage10.2174/1381612043384664 ↗
31. Breast tumor-on-chip: from the tumor microenvironment to medical applications10.1039/D3AN01295F ↗
32. Diversity models and applications of 3d breast tumor-on-a-chip10.3390/mi12070814 ↗
33. An engineered tumor-on-a-chip device with breast cancer–immune cell interactions for assessing T-cell recruitment10.1158/0008-5472.CAN-19-0342 ↗
34. Microfluidic technology for cell biology–related applications: a review10.1007/s10867-023-09646-y ↗
35. Microfluidic chip-based technologies: emerging platforms for cancer diagnosis10.1186/1472-6750-13-76 ↗
36. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review
37. Microfluidic lab-on-a-chip for studies of cell migration under spatial confinement10.3390/bios12080604 ↗
38. Extracellular matrix structure10.1016/j.addr.2015.11.001 ↗
39. Magnetic response of gelatin ferrogels across the sol–gel transition: the influence of high energy crosslinking on thermal stability10.1039/C5SM02695D ↗
40. Interplay between stiffness and degradation of architectured gelatin hydrogels leads to differential modulation of chondrogenesis. in vitro and in vivo10.1016/j.actbio.2018.01.025 ↗
41. Tumor microenvironment‐activatable nanoenzymes for mechanical remodeling of extracellular matrix and enhanced tumor chemotherapy10.1002/adfm.202007544 ↗
43. Consideration of the cellular microenvironment: physiologically relevant co-culture systems in drug discovery10.1016/j.addr.2014.01.013 ↗
44. Biosynthetic, biomimetic, and self-assembled vascularized organ-on-a-chip systems10.1016/j.biomaterials.2020.120556 ↗
45. Microfabricated tuneable and transferable porous PDMS membranes for organs-on-chips10.1038/s41598-018-31912-6 ↗
46. Liver sinusoid on a chip: long‐term layered co‐culture of primary rat hepatocytes and endothelial cells in microfluidic platforms10.1002/bit.25659 ↗
47. A novel organ-chip system emulates three-dimensional architecture of the human epithelia and the mechanical forces acting on it10.1016/j.biomaterials.2021.120957 ↗
48. Advances in organ-on-a-chip materials and devices10.1021/acsabm.2c00041 ↗
49. Organ-on-a-chip: design and simulation of various microfluidic channel geometries for the influence of fluid dynamic parameters10.3390/app12083829 ↗
50. PDMS organ-on-chip design and fabrication: strategies for improving fluidic integration and chip robustness of rapidly prototyped microfluidic in vitro models10.3390/mi13101573 ↗
51. Collagen I based enzymatically degradable membranes for organ-on-a-chip barrier models10.1021/acsbiomaterials.0c00297 ↗
52. Thin and stretchable extracellular matrix (ECM) membrane reinforced by nanofiber scaffolds for developing in vitro barrier models10.1088/1758-5090/ac4dd7 ↗
53. Tunable in situ synthesis of ultrathin extracellular matrix‐derived membranes in organ‐on‐a‐chip devices10.1002/adhm.202401158 ↗
54. Biophysical analysis of fluid shear stress induced cellular deformation in a microfluidic device10.1063/1.5063824 ↗
55. Enrichment of cancer stem-like cells by controlling oxygen, glucose and fluid shear stress in a microfluidic spheroid culture device10.1016/j.jsamd.2022.100439 ↗
56. Apigenin induced MCF‐7 cell apoptosis‐associated reactive oxygen species10.1002/sca.21170 ↗
57. Apoptosis induction by alantolactone in breast cancer MDA-MB-231 cells through reactive oxygen species-mediated mitochondrion-dependent pathway10.1007/s12272-017-0990-2 ↗
58. The matrix reorganized: extracellular matrix remodeling and integrin signaling10.1016/j.ceb.2006.08.009 ↗
59. Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression10.1038/nrc3789 ↗
60. In vitro cancer cell–ECM interactions inform in vivo cancer treatment10.1016/j.addr.2015.10.007 ↗
61. Extracellular matrix-cell interactions: focus on therapeutic applications10.1016/j.cellsig.2019.109487 ↗
62. Physico-mechanical aspects of extracellular matrix influences on tumorigenic behaviors10.1016/j.semcancer.2010.04.004 ↗
63. From cell–ECM interactions to tissue engineering10.1002/jcp.10471 ↗
64. Reactive oxygen species in cancer10.3109/10715761003667554 ↗
65. The two faces of reactive oxygen species in cancer10.1146/annurev-cancerbio-041916-065808 ↗
66. Reactive oxygen species in cancer: current findings and future directions10.1111/cas.15068 ↗
67. MCF-7 breast carcinoma cells do not express caspase-310.1007/s10549-008-0217-9 ↗
68. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy10.1038/sj.onc.1209608 ↗
69. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene10.1016/0092-8674(95)90412-3 ↗
70. Bax directly induces release of cytochrome c from isolated mitochondria10.1073/pnas.95.9.4997 ↗
71. Cytochrome C-mediated apoptosis10.1146/annurev.biochem.73.011303.073706 ↗
72. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release10.1074/jbc.275.10.7337 ↗